Recent advances in the diagnosis and treatment of stroke

Survey of Ophthalmology

Volumn 45, Issue 4, 2001, Pages 317-330

  McCullough, Louise D ^a   Beauchamp, N B ^a   Wityk, Robert ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Magnetic resonance imaging; Neuroprotection; Stroke; Thrombolytics

Indexed keywords

CITICOLINE; CLOMETHIAZOLE; FIBRINOLYTIC AGENT; FOSPHENYTOIN SODIUM; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; LAMOTRIGINE; LIFARIZINE; LUBELUZOLE; NIMODIPINE; PIRACETAM; UROKINASE; VIGABATRIN;

BLOOD CLOT LYSIS; BRAIN CIRCULATION; BRAIN FUNCTION; BRAIN ISCHEMIA; BRAIN MAPPING; DIAGNOSTIC TEST; DOSE RESPONSE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0035122682     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(00)00188-0     Document Type: Article

References (124)

1. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)
2. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
3. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care
4. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
5. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
6. Symptomatic intracerebral hemorrhage after t-PA for stroke: The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA stroke study group
7. Generalized efficacy of t-PA for acute stroke
8. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
9. Thrombolytic therapy with streptokinase in acute ischemic stroke
10. Tissue plasminogen activator for acute ischemic stroke
11. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
12. Current management of amaurosis fugax
13. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
14. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council
15. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke
16. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
17. Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients
18. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke
19. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging
20. Magnetic resonance imaging of acute stroke
21. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
22. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra
23. Interpretation of IST and CAST stroke trials
24. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis
25. Imaging of acute cerebral ischemia
26. MR diffusion imaging in stroke: Review and controversies
27. Intraarterial thrombolysis in vertebrobasilar occlusion
28. Antiplatelet therapy in acute cerebral ischemia
29. Noninvasive carotid artery testing. A meta-analytic review
30. The Lausanne Stroke Registry: Analysis of 1,000 consecutive patients with first stroke
31. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy
32. Recanalization therapies for acute ischemic stroke
33. Diagnosis of acute cerebral infarction: Comparison of CT and MRI imaging
34. Carotid artery disease and it's ocular manifestations
35. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
36. A randomized dose-response trial of citicoline in acute ischemic stroke patients
37. Randomized trial of citicoline in acute ischemic stroke
38. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial
39. Termination of Acute Stroke Studies Involving Selfotel Treatment
40. Treatment of acute ischemic stroke with piracetam
41. Opportunities for neuroprotection
42. The prolyse in acute cerebral thromboembolism trial (PROACT): Results of 6 mg dose tier
43. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
44. Clinical trial update: Neuroprotection against acute ischaemic stroke
45. Lubeluzole in acute ischemic stroke
46. Stroke prevention: Anti-platelet and anti-thrombolytic therapy
47. Stenting in the carotid artery: Initial experience in 110 patients
48. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
49. Trials of streptokinase in severe acute ischaemic stroke
50. New techniques in magnetic resonance imaging
51. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
52. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours
53. Lacunes: Small deep cerebral infarcts
54. Transient monocular blindeness associated with hemiplegia
55. Evolving stroke and the ischemic penumbra
56. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial
57. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke
58. Recent advances in stroke therapy
59. Clinical sensitivity and specificity of diffusion-weighted MRI in hyperacute stroke
60. Diffusion-weighted MR imaging: Diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset
61. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke
62. Lubeluzole treatment of acute ischemic stroke
63. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy
64. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
65. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
66. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
67. Prevention of stroke in patients with nonvalvular atrial fibrillation
68. The ischemic penumbra
69. Cerebrovascular ultrasound
70. Neuroprotective therapy
71. Termination of trial of streptokinase in severe acute ischemic stroke
72. Carotid artery: Prospective blinded comparison of two-dimensional time-of-flight MR angiography with conventional angiography and duplex US
73. Effects of tissue plasminogen activator for acute ischemic stroke at one year
74. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study
75. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome
76. Endovascular management of extracranial carotid artery dissection achieved using stent angioplasty
77. Acute and chronic stroke: Navigated spin-echo diffusion-weighted MR imaging
78. Evaluation of the extracranial carotid arteries: Correlation of magnetic resonance angiography, duplex ultrasonography, and conventional angiography
79. Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats
80. Magnetic resonance versus computed tomographic imaging in acute stroke
81. Meta-analysis of oral nimodipine trials in acute ischemic stroke
82. Short-term arteriographic and clinical outcome after cerebral angioplasty and stenting for intracranial vertebrobasilar and carotid atherosclerotic occlusive disease
83. Early detection of regional cerebral ischemia in cats: Comparison of diffusion- and T2-weighted MRI and spectroscopy
84. Neuroprotection for acute stroke: Making clinical trials work
85. Eye-movement abnormalities
86. Intracranial vertebrobasilar stenosis: Angioplasty and follow-up
87. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke
88. New reasons for early use of MRI in stroke
89. Multislice diffusion mapping for 3-D evolution of cerebral ischemia in a rat stroke model
90. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator
91. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI
92. Emerging therapies for acute ischemic stroke
93. Retinal stroke. Is the patient at risk?
94. A standardized MRI stroke protocol: Comparison with CT in hyperacute intracerebral hemorrhage
95. Microcatheter urokinase infusion in central retinal artery occlusion
96. Time course of lesion development in patients with acute stroke: Serial diffusion- and hemodynamic-weighted magnetic resonance imaging
97. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial
98. Diffusion-weighted MRI in acute subcortical infarction
99. Hyperacute stroke: Evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging
100. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification
101. Combination therapy with neuroprotectants and thrombolytics in acute ischaemic stroke
102. Intravenous heparin for acute stroke: What can we learn from the megatrials?
103. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
104. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience
105. Early CT finding in cerebral infarction: Obscuration of the lentiform nucleus
106. Diffusion and perfusion magnetic resonance imaging for the evaluation of acute stroke: Potential use in guiding thrombolytic therapy
107. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke
108. Loss of the insular ribbon: Another early CT sign of acute middle cerebral artery infarction
109. Absolute quantitation of diffusion constants in human stroke
110. Diffusion-weighted magnetic resonance imaging in acute stroke
111. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk
112. The Clomethiazole Acute Stroke Study (CLASS). Efficacy results in a subgroup of 545 with fatal anterior circulation syndrome
113. The Clomethiazole Acute Stroke Study (CLASS). Results of a randomised controlled study of clomethiazole versus placebo in 1,360 acute stroke patients
114. Pitfalls and potential of clinical diffusion-weighted MR imaging in acute stroke
115. Fast magnetic resonance diffusion-weighted imaging of acute human stroke
116. Time course of diffusion imaging abnormalities in human stroke
117. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
118. Selective intra-arterial fibrinolysis of acute central retinal artery occlusion
119. Intra-arterial thrombolysis in acute basilar artery thromboembolism: The initial Mayo Clinic experience
120. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator
121. MR imaging of cerebral Ischemia: Findings in the first 24 hours